Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Military Personnel | 19 | 2022 | 84 | 2.680 |
Why?
|
Anti-Infective Agents | 5 | 2023 | 43 | 2.360 |
Why?
|
HIV Infections | 13 | 2022 | 253 | 1.950 |
Why?
|
Sepsis | 3 | 2022 | 138 | 1.750 |
Why?
|
Disaster Planning | 3 | 2021 | 29 | 1.680 |
Why?
|
Critical Care | 5 | 2022 | 115 | 1.490 |
Why?
|
Anti-Bacterial Agents | 9 | 2023 | 283 | 1.440 |
Why?
|
Bacterial Infections | 2 | 2022 | 41 | 1.320 |
Why?
|
Humans | 77 | 2023 | 28999 | 1.180 |
Why?
|
Coronavirus Infections | 3 | 2020 | 72 | 1.080 |
Why?
|
Escherichia coli Infections | 9 | 2020 | 37 | 1.080 |
Why?
|
Pneumonia, Viral | 3 | 2020 | 77 | 1.070 |
Why?
|
Virus Diseases | 2 | 2022 | 18 | 0.990 |
Why?
|
Clostridium Infections | 1 | 2023 | 9 | 0.970 |
Why?
|
Leptospirosis | 4 | 2018 | 4 | 0.920 |
Why?
|
Intensive Care Units | 3 | 2020 | 126 | 0.920 |
Why?
|
Public Health | 2 | 2020 | 70 | 0.900 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 6 | 2019 | 155 | 0.870 |
Why?
|
Adult | 34 | 2023 | 8644 | 0.850 |
Why?
|
Ficusin | 2 | 2011 | 5 | 0.810 |
Why?
|
Dengue Virus | 2 | 2011 | 4 | 0.810 |
Why?
|
Dengue Vaccines | 2 | 2011 | 3 | 0.810 |
Why?
|
Travel | 4 | 2017 | 14 | 0.810 |
Why?
|
Decision Making | 1 | 2022 | 189 | 0.810 |
Why?
|
Diarrhea | 8 | 2020 | 56 | 0.800 |
Why?
|
Resource Allocation | 1 | 2020 | 18 | 0.790 |
Why?
|
Influenza, Human | 5 | 2020 | 119 | 0.770 |
Why?
|
Triage | 1 | 2020 | 69 | 0.740 |
Why?
|
Antigens, Bacterial | 4 | 2018 | 17 | 0.700 |
Why?
|
Herpesvirus 3, Human | 2 | 2019 | 3 | 0.700 |
Why?
|
Male | 41 | 2023 | 18231 | 0.690 |
Why?
|
Biomedical Research | 1 | 2019 | 164 | 0.660 |
Why?
|
Patient Acceptance of Health Care | 2 | 2016 | 158 | 0.650 |
Why?
|
Enterotoxigenic Escherichia coli | 6 | 2020 | 15 | 0.620 |
Why?
|
Peru | 14 | 2020 | 18 | 0.620 |
Why?
|
Military Medicine | 5 | 2020 | 25 | 0.620 |
Why?
|
Mass Vaccination | 1 | 2016 | 7 | 0.620 |
Why?
|
Reagins | 2 | 2013 | 2 | 0.600 |
Why?
|
Leprosy, Multibacillary | 1 | 2015 | 1 | 0.570 |
Why?
|
Influenza Vaccines | 1 | 2016 | 75 | 0.570 |
Why?
|
Staphylococcal Infections | 2 | 2013 | 59 | 0.560 |
Why?
|
Brucella melitensis | 3 | 2013 | 3 | 0.550 |
Why?
|
Female | 35 | 2023 | 18453 | 0.550 |
Why?
|
Neurocysticercosis | 1 | 2014 | 5 | 0.530 |
Why?
|
Cerebral Ventricles | 1 | 2014 | 11 | 0.530 |
Why?
|
United States | 19 | 2022 | 3700 | 0.530 |
Why?
|
Disease Outbreaks | 6 | 2021 | 35 | 0.520 |
Why?
|
Plasmodium vivax | 1 | 2013 | 1 | 0.510 |
Why?
|
Malaria, Vivax | 1 | 2013 | 1 | 0.510 |
Why?
|
Virus Shedding | 1 | 2013 | 3 | 0.510 |
Why?
|
Daptomycin | 1 | 2013 | 3 | 0.510 |
Why?
|
Chickenpox Vaccine | 1 | 2013 | 4 | 0.510 |
Why?
|
Chickenpox | 1 | 2013 | 5 | 0.510 |
Why?
|
Syphilis | 1 | 2013 | 5 | 0.510 |
Why?
|
Nephritis | 1 | 2013 | 17 | 0.510 |
Why?
|
Leptospira interrogans | 1 | 2013 | 1 | 0.510 |
Why?
|
Fever of Unknown Origin | 1 | 2013 | 9 | 0.510 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2013 | 12 | 0.510 |
Why?
|
Antibodies, Bacterial | 5 | 2019 | 28 | 0.500 |
Why?
|
Young Adult | 13 | 2021 | 2409 | 0.490 |
Why?
|
Fever | 1 | 2013 | 56 | 0.490 |
Why?
|
Campylobacter Infections | 3 | 2020 | 6 | 0.480 |
Why?
|
Emergency Service, Hospital | 1 | 2016 | 428 | 0.470 |
Why?
|
Middle Aged | 21 | 2020 | 11242 | 0.440 |
Why?
|
Antiviral Agents | 3 | 2020 | 107 | 0.440 |
Why?
|
Viral Load | 3 | 2020 | 54 | 0.430 |
Why?
|
Bacteria, Anaerobic | 1 | 2011 | 3 | 0.430 |
Why?
|
Peritoneal Diseases | 1 | 2011 | 4 | 0.430 |
Why?
|
Biliary Tract Diseases | 1 | 2011 | 8 | 0.430 |
Why?
|
Virus Inactivation | 1 | 2011 | 1 | 0.430 |
Why?
|
Disinfectants | 1 | 2011 | 2 | 0.430 |
Why?
|
Adenosine Monophosphate | 2 | 2020 | 6 | 0.420 |
Why?
|
HIV-1 | 2 | 2022 | 41 | 0.410 |
Why?
|
Alanine | 2 | 2020 | 26 | 0.410 |
Why?
|
Culex | 1 | 2010 | 1 | 0.410 |
Why?
|
Insect Bites and Stings | 1 | 2010 | 4 | 0.410 |
Why?
|
Blister | 1 | 2010 | 7 | 0.410 |
Why?
|
Critical Illness | 3 | 2022 | 85 | 0.410 |
Why?
|
Severe Acute Respiratory Syndrome | 2 | 2020 | 9 | 0.400 |
Why?
|
Escherichia coli Vaccines | 2 | 2020 | 10 | 0.390 |
Why?
|
Antibodies, Viral | 3 | 2019 | 50 | 0.380 |
Why?
|
Anti-HIV Agents | 2 | 2020 | 43 | 0.380 |
Why?
|
Azithromycin | 4 | 2017 | 13 | 0.360 |
Why?
|
Neurosyphilis | 1 | 2008 | 3 | 0.350 |
Why?
|
Eye Diseases | 1 | 2008 | 7 | 0.350 |
Why?
|
Fluoroquinolones | 2 | 2020 | 10 | 0.350 |
Why?
|
Hemorrhagic Fever, Ebola | 2 | 2019 | 2 | 0.340 |
Why?
|
Escherichia coli | 5 | 2017 | 78 | 0.340 |
Why?
|
Respiration, Artificial | 4 | 2020 | 98 | 0.340 |
Why?
|
Influenza A Virus, H1N1 Subtype | 3 | 2020 | 48 | 0.330 |
Why?
|
Cholera Toxin | 2 | 2020 | 5 | 0.330 |
Why?
|
Brucellosis | 3 | 2013 | 4 | 0.320 |
Why?
|
Campylobacter jejuni | 2 | 2020 | 3 | 0.320 |
Why?
|
Sentinel Surveillance | 3 | 2011 | 9 | 0.320 |
Why?
|
Acute Disease | 3 | 2017 | 248 | 0.320 |
Why?
|
Drug Resistance, Bacterial | 2 | 2020 | 36 | 0.310 |
Why?
|
Coccidioidomycosis | 2 | 2022 | 3 | 0.310 |
Why?
|
Cohort Studies | 9 | 2023 | 1694 | 0.310 |
Why?
|
Leptospira | 2 | 2018 | 2 | 0.310 |
Why?
|
Viremia | 2 | 2019 | 5 | 0.300 |
Why?
|
Treatment Outcome | 8 | 2020 | 3149 | 0.300 |
Why?
|
Purines | 2 | 2020 | 16 | 0.290 |
Why?
|
Antiretroviral Therapy, Highly Active | 3 | 2020 | 39 | 0.290 |
Why?
|
HIV | 3 | 2019 | 22 | 0.280 |
Why?
|
Hospitalization | 4 | 2023 | 403 | 0.280 |
Why?
|
Prospective Studies | 6 | 2022 | 1989 | 0.270 |
Why?
|
Adolescent | 6 | 2020 | 3232 | 0.260 |
Why?
|
Communicable Disease Control | 2 | 2016 | 12 | 0.250 |
Why?
|
Surge Capacity | 2 | 2020 | 9 | 0.250 |
Why?
|
Animals | 11 | 2020 | 7360 | 0.250 |
Why?
|
Internationality | 2 | 2020 | 21 | 0.250 |
Why?
|
Microbial Sensitivity Tests | 5 | 2020 | 50 | 0.240 |
Why?
|
Quality of Life | 2 | 2020 | 854 | 0.240 |
Why?
|
Double-Blind Method | 5 | 2020 | 521 | 0.240 |
Why?
|
Case-Control Studies | 6 | 2022 | 927 | 0.240 |
Why?
|
Anthrax | 1 | 2022 | 5 | 0.240 |
Why?
|
Bacillus anthracis | 1 | 2022 | 9 | 0.240 |
Why?
|
Antitoxins | 1 | 2022 | 6 | 0.240 |
Why?
|
Risk-Taking | 2 | 2020 | 88 | 0.230 |
Why?
|
HIV Seropositivity | 1 | 2021 | 11 | 0.220 |
Why?
|
Immunoglobulin G | 4 | 2019 | 101 | 0.220 |
Why?
|
Pericarditis | 3 | 2013 | 6 | 0.220 |
Why?
|
Afghanistan | 2 | 2017 | 5 | 0.210 |
Why?
|
RNA, Viral | 1 | 2021 | 53 | 0.210 |
Why?
|
Naval Medicine | 1 | 2021 | 1 | 0.210 |
Why?
|
Time Factors | 4 | 2020 | 2030 | 0.210 |
Why?
|
Azetidines | 1 | 2020 | 9 | 0.210 |
Why?
|
Adhesins, Escherichia coli | 1 | 2020 | 3 | 0.210 |
Why?
|
Ventilators, Mechanical | 1 | 2020 | 6 | 0.210 |
Why?
|
Hospitals, Military | 2 | 2020 | 7 | 0.210 |
Why?
|
Alum Compounds | 2 | 2011 | 4 | 0.200 |
Why?
|
DNA Gyrase | 1 | 2020 | 1 | 0.200 |
Why?
|
Medical Staff, Hospital | 1 | 2020 | 17 | 0.200 |
Why?
|
Antibodies, Neutralizing | 2 | 2011 | 17 | 0.200 |
Why?
|
Point Mutation | 1 | 2020 | 18 | 0.200 |
Why?
|
Sexually Transmitted Diseases | 1 | 2020 | 29 | 0.200 |
Why?
|
Drug Industry | 1 | 2020 | 16 | 0.200 |
Why?
|
Pyrazoles | 1 | 2020 | 63 | 0.200 |
Why?
|
Sulfonamides | 1 | 2020 | 67 | 0.200 |
Why?
|
California | 2 | 2022 | 61 | 0.200 |
Why?
|
Pharmaceutical Preparations | 1 | 2020 | 27 | 0.200 |
Why?
|
Sexual Behavior | 1 | 2020 | 75 | 0.200 |
Why?
|
Adjuvants, Immunologic | 2 | 2011 | 52 | 0.190 |
Why?
|
Immunization, Passive | 1 | 2019 | 3 | 0.190 |
Why?
|
Photorefractive Keratectomy | 1 | 2019 | 3 | 0.190 |
Why?
|
Myopia | 1 | 2019 | 5 | 0.190 |
Why?
|
Respiratory Insufficiency | 1 | 2020 | 60 | 0.190 |
Why?
|
Patient Care Team | 1 | 2021 | 122 | 0.190 |
Why?
|
Lasers, Excimer | 1 | 2019 | 8 | 0.190 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2020 | 48 | 0.190 |
Why?
|
Plasma | 1 | 2019 | 16 | 0.190 |
Why?
|
Homosexuality, Male | 1 | 2020 | 65 | 0.190 |
Why?
|
Cornea | 1 | 2019 | 12 | 0.190 |
Why?
|
Melioidosis | 1 | 2019 | 2 | 0.190 |
Why?
|
Continuity of Patient Care | 1 | 2020 | 62 | 0.190 |
Why?
|
Measles | 1 | 2019 | 2 | 0.190 |
Why?
|
Influenza A virus | 1 | 2019 | 21 | 0.190 |
Why?
|
CD4 Lymphocyte Count | 4 | 2020 | 32 | 0.190 |
Why?
|
Herpes Zoster | 1 | 2019 | 10 | 0.190 |
Why?
|
Gastroenteritis | 2 | 2017 | 12 | 0.190 |
Why?
|
Emergencies | 1 | 2019 | 48 | 0.190 |
Why?
|
Child | 5 | 2020 | 2130 | 0.190 |
Why?
|
Ciprofloxacin | 3 | 2020 | 12 | 0.180 |
Why?
|
Health Policy | 1 | 2019 | 73 | 0.180 |
Why?
|
Immunoglobulin M | 3 | 2018 | 16 | 0.180 |
Why?
|
Angiostrongylus cantonensis | 1 | 2018 | 1 | 0.180 |
Why?
|
Strongylida Infections | 1 | 2018 | 2 | 0.180 |
Why?
|
Stress Disorders, Post-Traumatic | 1 | 2019 | 39 | 0.180 |
Why?
|
Zoonoses | 1 | 2018 | 3 | 0.180 |
Why?
|
Serologic Tests | 1 | 2018 | 9 | 0.180 |
Why?
|
Central Nervous System Diseases | 1 | 2018 | 12 | 0.180 |
Why?
|
Respiratory Tract Infections | 1 | 2018 | 40 | 0.170 |
Why?
|
Mental Disorders | 1 | 2019 | 99 | 0.170 |
Why?
|
Myocardial Infarction | 1 | 2022 | 413 | 0.170 |
Why?
|
Aged | 9 | 2020 | 9677 | 0.170 |
Why?
|
Incidence | 5 | 2022 | 1097 | 0.170 |
Why?
|
Emergency Medical Services | 1 | 2020 | 153 | 0.170 |
Why?
|
Ships | 2 | 2021 | 2 | 0.160 |
Why?
|
Polymerase Chain Reaction | 3 | 2012 | 167 | 0.160 |
Why?
|
Travel Medicine | 1 | 2017 | 1 | 0.160 |
Why?
|
Aotidae | 2 | 2020 | 2 | 0.160 |
Why?
|
Genetic Predisposition to Disease | 1 | 2021 | 966 | 0.160 |
Why?
|
Practice Guidelines as Topic | 1 | 2020 | 381 | 0.150 |
Why?
|
Escherichia coli Proteins | 3 | 2011 | 26 | 0.150 |
Why?
|
Alcohol Drinking | 1 | 2019 | 230 | 0.150 |
Why?
|
Prognosis | 1 | 2020 | 1384 | 0.150 |
Why?
|
DNA, Bacterial | 3 | 2012 | 17 | 0.150 |
Why?
|
Norovirus | 2 | 2017 | 3 | 0.150 |
Why?
|
Mycobacterium leprae | 1 | 2015 | 1 | 0.140 |
Why?
|
Bacterial Typing Techniques | 2 | 2012 | 9 | 0.140 |
Why?
|
Neoplasms | 1 | 2022 | 644 | 0.140 |
Why?
|
Health Personnel | 1 | 2016 | 107 | 0.140 |
Why?
|
Communicable Diseases, Emerging | 2 | 2011 | 2 | 0.130 |
Why?
|
Pilot Projects | 1 | 2016 | 465 | 0.130 |
Why?
|
Health Services Needs and Demand | 1 | 2015 | 65 | 0.130 |
Why?
|
Shiga-Toxigenic Escherichia coli | 2 | 2011 | 3 | 0.130 |
Why?
|
Infant | 5 | 2018 | 936 | 0.130 |
Why?
|
Risk Factors | 5 | 2019 | 3569 | 0.130 |
Why?
|
Biopsy | 1 | 2015 | 240 | 0.130 |
Why?
|
Skin Diseases, Bacterial | 1 | 2013 | 3 | 0.130 |
Why?
|
Syphilis Serodiagnosis | 1 | 2013 | 3 | 0.130 |
Why?
|
Soft Tissue Infections | 1 | 2013 | 10 | 0.130 |
Why?
|
False Positive Reactions | 1 | 2013 | 23 | 0.130 |
Why?
|
Drug Therapy, Combination | 2 | 2020 | 285 | 0.130 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 1 | 2013 | 25 | 0.130 |
Why?
|
Child, Preschool | 5 | 2018 | 1156 | 0.120 |
Why?
|
Vaccination | 2 | 2013 | 100 | 0.120 |
Why?
|
Demography | 1 | 2013 | 113 | 0.120 |
Why?
|
Lactoferrin | 1 | 2013 | 2 | 0.120 |
Why?
|
Gangliosides | 1 | 2013 | 6 | 0.120 |
Why?
|
Foodborne Diseases | 1 | 2013 | 2 | 0.120 |
Why?
|
Skin | 1 | 2015 | 205 | 0.120 |
Why?
|
Severity of Illness Index | 3 | 2022 | 890 | 0.120 |
Why?
|
Myocarditis | 1 | 2013 | 5 | 0.120 |
Why?
|
Campylobacter coli | 1 | 2012 | 2 | 0.120 |
Why?
|
Intestinal Mucosa | 1 | 2013 | 63 | 0.120 |
Why?
|
Repetitive Sequences, Nucleic Acid | 1 | 2012 | 6 | 0.120 |
Why?
|
Shigella | 1 | 2012 | 7 | 0.120 |
Why?
|
Mice | 3 | 2020 | 2331 | 0.120 |
Why?
|
Hemoptysis | 1 | 2011 | 3 | 0.110 |
Why?
|
Caliciviridae Infections | 1 | 2011 | 2 | 0.110 |
Why?
|
Drug Resistance, Microbial | 1 | 2011 | 10 | 0.110 |
Why?
|
Dengue | 1 | 2011 | 4 | 0.110 |
Why?
|
Immunization, Secondary | 1 | 2011 | 9 | 0.110 |
Why?
|
Gentamicins | 1 | 2011 | 4 | 0.110 |
Why?
|
Comorbidity | 3 | 2020 | 557 | 0.110 |
Why?
|
Rifampin | 1 | 2011 | 7 | 0.110 |
Why?
|
Vibrio parahaemolyticus | 1 | 2010 | 1 | 0.100 |
Why?
|
Aeromonas hydrophila | 1 | 2010 | 1 | 0.100 |
Why?
|
Oxygen Inhalation Therapy | 2 | 2020 | 7 | 0.100 |
Why?
|
Doxycycline | 1 | 2011 | 24 | 0.100 |
Why?
|
Fimbriae Proteins | 1 | 2010 | 5 | 0.100 |
Why?
|
Guidelines as Topic | 1 | 2011 | 45 | 0.100 |
Why?
|
Food Handling | 1 | 2010 | 6 | 0.100 |
Why?
|
Seafood | 1 | 2010 | 11 | 0.100 |
Why?
|
Respiratory Tract Diseases | 1 | 2011 | 36 | 0.100 |
Why?
|
South America | 1 | 2010 | 3 | 0.100 |
Why?
|
Gastrointestinal Diseases | 1 | 2011 | 42 | 0.100 |
Why?
|
Phenotype | 2 | 2023 | 664 | 0.100 |
Why?
|
Australia | 2 | 2021 | 29 | 0.100 |
Why?
|
Fruit | 1 | 2010 | 57 | 0.100 |
Why?
|
Injections, Intradermal | 1 | 2009 | 6 | 0.100 |
Why?
|
Vaccines, Inactivated | 1 | 2009 | 36 | 0.100 |
Why?
|
Hospital Mortality | 2 | 2020 | 190 | 0.090 |
Why?
|
Cardiolipins | 1 | 2008 | 2 | 0.090 |
Why?
|
Phosphatidylcholines | 1 | 2008 | 21 | 0.090 |
Why?
|
Cerebrospinal Fluid | 1 | 2008 | 13 | 0.090 |
Why?
|
Sulfones | 1 | 2008 | 14 | 0.090 |
Why?
|
Magnetic Resonance Imaging | 1 | 2014 | 1210 | 0.090 |
Why?
|
Polymorphism, Genetic | 1 | 2009 | 220 | 0.090 |
Why?
|
Piperazines | 1 | 2008 | 56 | 0.090 |
Why?
|
Honduras | 1 | 2017 | 1 | 0.090 |
Why?
|
Loperamide | 1 | 2017 | 1 | 0.090 |
Why?
|
Djibouti | 1 | 2017 | 1 | 0.090 |
Why?
|
Kenya | 1 | 2017 | 6 | 0.090 |
Why?
|
Retrospective Studies | 4 | 2022 | 3073 | 0.080 |
Why?
|
Sensitivity and Specificity | 2 | 2019 | 524 | 0.080 |
Why?
|
Aneurysm, Infected | 1 | 2006 | 4 | 0.080 |
Why?
|
Cholesterol | 1 | 2008 | 236 | 0.080 |
Why?
|
Methicillin Resistance | 1 | 2006 | 12 | 0.080 |
Why?
|
Aneurysm, False | 1 | 2006 | 13 | 0.080 |
Why?
|
Community-Acquired Infections | 1 | 2006 | 31 | 0.080 |
Why?
|
Staphylococcus aureus | 1 | 2006 | 44 | 0.080 |
Why?
|
Feces | 2 | 2019 | 29 | 0.070 |
Why?
|
Aorta | 1 | 2006 | 113 | 0.070 |
Why?
|
Recombinant Proteins | 2 | 2018 | 246 | 0.070 |
Why?
|
Prevalence | 3 | 2012 | 912 | 0.070 |
Why?
|
Infection Control | 2 | 2016 | 20 | 0.060 |
Why?
|
Age Factors | 2 | 2018 | 1129 | 0.060 |
Why?
|
Convalescence | 1 | 2022 | 2 | 0.060 |
Why?
|
Bacillus cereus | 1 | 2022 | 1 | 0.060 |
Why?
|
Coccidioides | 1 | 2022 | 1 | 0.060 |
Why?
|
Plasmids | 1 | 2022 | 46 | 0.060 |
Why?
|
Enterotoxins | 2 | 2013 | 6 | 0.060 |
Why?
|
Interleukin-6 | 1 | 2023 | 227 | 0.060 |
Why?
|
Electrophoresis, Gel, Pulsed-Field | 2 | 2012 | 6 | 0.060 |
Why?
|
Serotyping | 2 | 2012 | 14 | 0.060 |
Why?
|
Goats | 2 | 2013 | 4 | 0.050 |
Why?
|
Leukocytes, Mononuclear | 1 | 2021 | 49 | 0.050 |
Why?
|
Portasystemic Shunt, Surgical | 1 | 2001 | 2 | 0.050 |
Why?
|
Esophageal and Gastric Varices | 1 | 2001 | 4 | 0.050 |
Why?
|
Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2001 | 3 | 0.050 |
Why?
|
Hypertension, Portal | 1 | 2001 | 10 | 0.050 |
Why?
|
Unsafe Sex | 1 | 2020 | 15 | 0.050 |
Why?
|
Guinea Pigs | 1 | 2020 | 12 | 0.050 |
Why?
|
Virulence Factors | 2 | 2011 | 7 | 0.050 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2001 | 19 | 0.050 |
Why?
|
Patient Care | 1 | 2021 | 35 | 0.050 |
Why?
|
Inventories, Hospital | 1 | 2020 | 1 | 0.050 |
Why?
|
Ritonavir | 1 | 2020 | 2 | 0.050 |
Why?
|
Isoleucine | 1 | 2020 | 6 | 0.050 |
Why?
|
Extracorporeal Membrane Oxygenation | 1 | 2020 | 24 | 0.050 |
Why?
|
Disasters | 1 | 2020 | 11 | 0.050 |
Why?
|
Threonine | 1 | 2020 | 12 | 0.050 |
Why?
|
Hydroxychloroquine | 1 | 2020 | 10 | 0.050 |
Why?
|
Influenza A Virus, H3N2 Subtype | 1 | 2020 | 22 | 0.050 |
Why?
|
Recombinant Fusion Proteins | 1 | 2020 | 79 | 0.050 |
Why?
|
Amino Acid Substitution | 1 | 2020 | 37 | 0.050 |
Why?
|
Hypnotics and Sedatives | 1 | 2020 | 30 | 0.050 |
Why?
|
DNA Mutational Analysis | 1 | 2020 | 69 | 0.050 |
Why?
|
Interdisciplinary Communication | 1 | 2020 | 53 | 0.050 |
Why?
|
United States Food and Drug Administration | 1 | 2020 | 43 | 0.050 |
Why?
|
Drug Combinations | 1 | 2020 | 83 | 0.050 |
Why?
|
Liver Cirrhosis | 1 | 2001 | 82 | 0.050 |
Why?
|
Protease Inhibitors | 1 | 2020 | 15 | 0.050 |
Why?
|
CD4-CD8 Ratio | 1 | 2020 | 2 | 0.050 |
Why?
|
Seasons | 1 | 2020 | 96 | 0.050 |
Why?
|
Natural History | 1 | 2019 | 1 | 0.050 |
Why?
|
Neuropsychological Tests | 1 | 2021 | 388 | 0.050 |
Why?
|
Measles Vaccine | 1 | 2019 | 1 | 0.050 |
Why?
|
Burkholderia pseudomallei | 1 | 2019 | 1 | 0.050 |
Why?
|
History, 21st Century | 1 | 2019 | 50 | 0.050 |
Why?
|
History, 20th Century | 1 | 2019 | 72 | 0.050 |
Why?
|
Herpes Zoster Vaccine | 1 | 2019 | 4 | 0.050 |
Why?
|
Genetic Variation | 1 | 2021 | 282 | 0.050 |
Why?
|
Treatment Failure | 1 | 2019 | 163 | 0.050 |
Why?
|
Visual Acuity | 1 | 2019 | 67 | 0.050 |
Why?
|
Administration, Intranasal | 1 | 2019 | 30 | 0.050 |
Why?
|
Length of Stay | 1 | 2020 | 296 | 0.050 |
Why?
|
Statistics, Nonparametric | 1 | 2019 | 137 | 0.050 |
Why?
|
Antibodies, Monoclonal | 2 | 2010 | 190 | 0.040 |
Why?
|
Primates | 1 | 2019 | 99 | 0.040 |
Why?
|
Mass Screening | 1 | 2020 | 206 | 0.040 |
Why?
|
Chi-Square Distribution | 1 | 2019 | 308 | 0.040 |
Why?
|
Longitudinal Studies | 1 | 2020 | 730 | 0.040 |
Why?
|
Bayes Theorem | 1 | 2018 | 63 | 0.040 |
Why?
|
Continental Population Groups | 1 | 2019 | 233 | 0.040 |
Why?
|
Campylobacter | 1 | 2017 | 2 | 0.040 |
Why?
|
Multivariate Analysis | 1 | 2018 | 667 | 0.040 |
Why?
|
Sex Factors | 1 | 2018 | 652 | 0.040 |
Why?
|
Proportional Hazards Models | 1 | 2018 | 722 | 0.040 |
Why?
|
Clinical Protocols | 1 | 2016 | 89 | 0.040 |
Why?
|
Intestinal Diseases, Parasitic | 1 | 2015 | 1 | 0.040 |
Why?
|
Rivers | 1 | 2015 | 2 | 0.040 |
Why?
|
Parasitic Diseases | 1 | 2015 | 5 | 0.040 |
Why?
|
Child Nutrition Disorders | 1 | 2015 | 4 | 0.040 |
Why?
|
Malaria | 1 | 2015 | 9 | 0.040 |
Why?
|
Disease Models, Animal | 1 | 2019 | 1018 | 0.030 |
Why?
|
Agglutination Tests | 1 | 2013 | 2 | 0.030 |
Why?
|
Bacterial Outer Membrane Proteins | 1 | 2013 | 5 | 0.030 |
Why?
|
Species Specificity | 1 | 2013 | 81 | 0.030 |
Why?
|
G(M1) Ganglioside | 1 | 2013 | 1 | 0.030 |
Why?
|
Lipoproteins | 1 | 2013 | 81 | 0.030 |
Why?
|
Chlorides | 1 | 2013 | 15 | 0.030 |
Why?
|
Ferric Compounds | 1 | 2013 | 14 | 0.030 |
Why?
|
Bacterial Proteins | 1 | 2013 | 69 | 0.030 |
Why?
|
Cheese | 1 | 2013 | 1 | 0.030 |
Why?
|
Food Microbiology | 1 | 2013 | 1 | 0.030 |
Why?
|
Contact Tracing | 1 | 2013 | 5 | 0.030 |
Why?
|
Smallpox Vaccine | 1 | 2013 | 2 | 0.030 |
Why?
|
Cattle | 1 | 2013 | 92 | 0.030 |
Why?
|
Police | 1 | 2013 | 22 | 0.030 |
Why?
|
Intestines | 1 | 2013 | 52 | 0.030 |
Why?
|
Rural Population | 1 | 2015 | 290 | 0.030 |
Why?
|
Receptors, Cell Surface | 1 | 2013 | 70 | 0.030 |
Why?
|
Protein Binding | 1 | 2013 | 185 | 0.030 |
Why?
|
Erythromycin | 1 | 2012 | 6 | 0.030 |
Why?
|
Health Status | 1 | 2015 | 381 | 0.030 |
Why?
|
DNA, Intergenic | 1 | 2012 | 9 | 0.030 |
Why?
|
Dysentery, Bacillary | 1 | 2012 | 13 | 0.030 |
Why?
|
Hawaii | 1 | 2011 | 3 | 0.030 |
Why?
|
Syndrome | 1 | 2011 | 67 | 0.030 |
Why?
|
Hemolysin Proteins | 1 | 2011 | 1 | 0.030 |
Why?
|
Adhesins, Bacterial | 1 | 2011 | 2 | 0.030 |
Why?
|
Laboratories | 1 | 2011 | 13 | 0.030 |
Why?
|
Shiga Toxin | 1 | 2011 | 2 | 0.030 |
Why?
|
Genes, Bacterial | 1 | 2011 | 7 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2013 | 650 | 0.030 |
Why?
|
Phylogeny | 1 | 2011 | 52 | 0.030 |
Why?
|
Microbial Viability | 1 | 2010 | 4 | 0.030 |
Why?
|
Communicable Diseases | 1 | 2011 | 19 | 0.030 |
Why?
|
Enteropathogenic Escherichia coli | 1 | 2010 | 3 | 0.030 |
Why?
|
Bacterial Adhesion | 1 | 2010 | 7 | 0.030 |
Why?
|
Nutritional Sciences | 1 | 2010 | 10 | 0.030 |
Why?
|
Antigens, Surface | 1 | 2010 | 17 | 0.030 |
Why?
|
Beverages | 1 | 2010 | 20 | 0.030 |
Why?
|
Hydrogen-Ion Concentration | 1 | 2010 | 66 | 0.030 |
Why?
|
Vegetables | 1 | 2010 | 39 | 0.030 |
Why?
|
Bacterial Toxins | 1 | 2010 | 16 | 0.030 |
Why?
|
Base Sequence | 1 | 2011 | 226 | 0.030 |
Why?
|
Forecasting | 1 | 2011 | 134 | 0.020 |
Why?
|
DNA Fingerprinting | 1 | 2009 | 7 | 0.020 |
Why?
|
Minisatellite Repeats | 1 | 2009 | 10 | 0.020 |
Why?
|
Dairy Products | 1 | 2009 | 12 | 0.020 |
Why?
|
Molecular Epidemiology | 1 | 2009 | 21 | 0.020 |
Why?
|
Occupational Exposure | 1 | 2013 | 285 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2009 | 123 | 0.020 |
Why?
|
Hospitals | 1 | 2009 | 75 | 0.020 |
Why?
|
Urban Population | 1 | 2009 | 79 | 0.020 |
Why?
|
Infant, Newborn | 1 | 2011 | 575 | 0.020 |
Why?
|
Genotype | 1 | 2009 | 827 | 0.020 |
Why?
|
Empyema, Pleural | 1 | 2006 | 6 | 0.020 |
Why?
|
Peritonitis | 1 | 2006 | 10 | 0.020 |
Why?
|
Pharyngeal Diseases | 1 | 2006 | 7 | 0.020 |
Why?
|
Buttocks | 1 | 2006 | 5 | 0.020 |
Why?
|
Myositis | 1 | 2006 | 10 | 0.020 |
Why?
|
Abscess | 1 | 2006 | 26 | 0.020 |
Why?
|
Antifungal Agents | 1 | 2006 | 33 | 0.020 |
Why?
|
Tracheostomy | 1 | 2006 | 27 | 0.020 |
Why?
|
Radiography | 1 | 2006 | 348 | 0.020 |
Why?
|
Costs and Cost Analysis | 1 | 2001 | 88 | 0.010 |
Why?
|
Risk Assessment | 1 | 2001 | 1319 | 0.010 |
Why?
|